Format

Send to

Choose Destination
Alzheimers Dement (Amst). 2019 Jan 12;11:85-97. doi: 10.1016/j.dadm.2018.11.003. eCollection 2019 Dec.

Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment.

Liu S1,2,3, Suzuki H3,4, Ito H3,4, Korenaga T3,4, Akatsu H5, Meno K3,4, Uchida K1,3.

Author information

1
Department of Molecular Biological Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
2
Department of Neuropsychiatry, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
3
Tsukuba Industrial Liaison and Cooperative Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan.
4
Research Division, MCBI. Inc., Ibaraki, Japan.
5
Fukusimura Hospital, Toyohashi, Aichi, Japan.

Abstract

Introduction:

Amyloid-β (Aβ) clearance is important for damage prevention in Alzheimer's disease. We investigated the utility of Aβ clearance proteins as biomarkers for mild cognitive impairment (MCI).

Methods:

Serum apolipoprotein (apo) A-I, compliment protein C3 (C3), transthyretin, and cholesterol levels were measured in 273 subjects, and we analyzed the relationship between these levels and brain atrophy and cerebral blood flow in 63 clinically diagnosed mild cognitive impairment, Alzheimer's disease, and nondemented disease control subjects.

Results:

ApoA-I and transthyretin levels and the active form of C3:native form of C3 ratio achieved an area under the curve of 0.89 (sensitivity: 83%, specificity: 90%) for detecting late mild cognitive impairment. Atrophy was associated with decreased apoA-I and high-density lipoprotein levels. Subjects with reduced cerebral blood flow had lower levels of active form of C3, apoA-I, high-density lipoprotein, and total cholesterol. Low native form of C3 and high active form of C3 levels were found in the hippocampi of patients with Alzheimer's disease.

Discussion:

Aβ clearance proteins in the serum are potential biomarkers for mild cognitive impairment evaluation.

KEYWORDS:

Alzheimer's disease; Biomarker; Complement protein; Microglia; Neuroinflammation

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center